With a market cap of $390 billion, New Brunswick, New Jersey-based Johnson & Johnson (JNJ) is a leading healthcare company. Operating across the pharmaceuticals, medical devices, and consumer products sectors, it develops a diverse range of products aimed at improving global health and well-being. The pharmaceutical giant is expected to announce its fiscal Q3 earnings results for 2024 before the market opens on Tuesday, Oct. 15. Ahead of this event, analysts expect JNJ to report a profit of $2.18 per share, a decrease of 18.1% from the previous year’s $2.66 per share. However, the company has …